Medpace

Medpace Holdings, Inc. is a global clinical research organization based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
The company started trading stock as a public firm in 2016.

History

August Troendle founded Medpace in Cincinnati, Ohio, in 1992 as Medical Research Services. Troendle first became interested in the CRO sector after working in both the regulatory and pharmaceutical area. He began his career as a reviewer with the FDA, specializing in the development of lipid lowering therapies to treat high cholesterol.
With a team of industry physicians, Jonathan Issacsohn and Evan Stein completed many early studies while at Medpace and Medpace Reference Laboratories on the use of statin therapies for the treatment of hypercholesterolemia. Another Medpace physician, David Orloff was regarded as an industry opinion leader in the study of metabolic diseases – most specifically diabetes and obesity. Troendle was honored for his work as a Medpace founder in 2012 by the Cincinnati Chamber of Commerce.
Medpace completed construction on a new campus in 2012 in Madisonville, a neighborhood on the eastern side of Cincinnati. The project encompassed revitalizing an urban brownfield site formerly occupied by NuTone, and creating a state of the art LEED certified campus.
In 2022, Medpace announced a $150 million capital investment to expand its headquarters in Cincinnati, Ohio, adding an estimated expansion of 1,500 new jobs.

Acquisitions

2007 – Medpace acquires Monax in the Czech Republic
2009 – Medpace acquires PharmaBrains AG in Switzerland
2010 – Medpace acquires Symbios, a medical device consultancy in Minneapolis, Minnesota
2010 – Medpace acquires Medical Consulting Dr. Schlichtiger, GmbH, in Germany
2012 – Medpace acquires MediTech BV, a medical device consultancy in the Netherlands.
Ownership

In 2011, CCMP Capital acquired 80% of the firm for. Three years later, in February 2014, CCMP auctioned their 80% stake; the winner was won by Cinven, who paid. In August 2017, Medpace went became a publicly traded company with its initial public offering, selling 8,050,000 shares of common stock.

Corporate affairs

Head Office Locations

Medpace Holdings, Inc. is headquartered in Cincinnati, Ohio, United States. The company’s main campus, known as the Medpace Campus, is located in the Madisonville neighborhood of Cincinnati and includes multiple office buildings, laboratories, and clinical facilities.
In addition to its headquarters, Medpace operates regional offices and clinical sites across North America, Europe, Asia, and Latin America to support global clinical trial operations.

Financial performance

Medpace Holdings, Inc. has demonstrated strong revenue and income growth since going public in 2016, maintaining a steady upward trajectory in operating and net income over the last several years.

Year	Revenue	Gross Profit	Net Income
2013	0.27	0.12	0.02
2015	0.36	0.15	-0.08
2017	0.43	0.17	0.04
2020	0.93	0.28	0.14
2021	1.14	0.33	0.18
2022	1.46	0.43	0.24
2023	1.89	0.52	0.28
2024	2.11	0.66	0.40